Difference between revisions of "Paclitaxel, nanoparticle albumin-bound (Abraxane)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m |
||
| Line 19: | Line 19: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *1/7/2005: FDA approved for "metastatic [[Breast cancer | breast cancer]], after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an [ | + | *1/7/2005: FDA approved for "metastatic [[Breast cancer | breast cancer]], after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an [[:Category:Anthracyclines|anthracycline]] unless clinically contraindicated."<ref name="insert"></ref> |
*10/11/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm FDA approved] for "locally advanced or metastatic [[Non-small cell lung cancer | Non-Small Cell Lung Cancer (NSCLC)]], as first-line treatment in combination with [[Carboplatin (Paraplatin) | carboplatin]], in patients who are not candidates for curative surgery or radiation therapy."<ref name="insert"></ref> | *10/11/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm FDA approved] for "locally advanced or metastatic [[Non-small cell lung cancer | Non-Small Cell Lung Cancer (NSCLC)]], as first-line treatment in combination with [[Carboplatin (Paraplatin) | carboplatin]], in patients who are not candidates for curative surgery or radiation therapy."<ref name="insert"></ref> | ||
*9/6/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367442.htm FDA approved] for treatment of "metastatic [[Pancreatic cancer | adenocarcinoma of the pancreas]] as first-line treatment, in combination with [[Gemcitabine (Gemzar) | gemcitabine]]."<ref name="insert"></ref> | *9/6/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367442.htm FDA approved] for treatment of "metastatic [[Pancreatic cancer | adenocarcinoma of the pancreas]] as first-line treatment, in combination with [[Gemcitabine (Gemzar) | gemcitabine]]."<ref name="insert"></ref> | ||
Revision as of 01:02, 14 May 2018
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. The nanoparticle albumin bound characteristic of Abraxane eliminates the need for it to be dissolved in Cremophor EL (polyoxyethylated castor oil) like Paclitaxel (Taxol) and the risk of hypersensitivity infusion reactions related to Cremophor.[1][2][3]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Paclitaxel, nanoparticle albumin-bound (Abraxane) package insert[1]
- Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (Chemocare)[4]
- Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1/7/2005: FDA approved for "metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated."[1]
- 10/11/2012: FDA approved for "locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy."[1]
- 9/6/2013: FDA approved for treatment of "metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine."[1]
Also known as
- Code name: ABI-007
- Generic names: ab-pac, ab-paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, paclitaxel protein-bound, paclitaxel protein-bound particles for injectable suspension (albumin-bound)
- Brand name: Abraxane
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Paclitaxel, nanoparticle albumin-bound (Abraxane) package insert
- ↑ Paclitaxel, nanoparticle albumin-bound (Abraxane) package insert (locally hosted backup)
- ↑ Abraxane manufacturer's website
- ↑ Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (Chemocare)
- ↑ Paclitaxel, nanoparticle albumin-bound (Abraxane) patient drug information (UpToDate)